J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitchell, D.
Right arrow Articles by Powell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, D.
Right arrow Articles by Powell, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers

DY Mitchell, RA Eusebio, NA Sacco-Gibson, KA Pallone, SC Kelly, JD Nesbitt, CP Brezovic, GA Thompson, and JH Powell

Risedronate is a pyridinyl bisphosphonate approved for the treatment of Paget's disease (US-FDA) and in development for the treatment and prevention of osteoporosis. This study examined risedronate pharmacokinetics and tolerability after oral administration using a randomized, double-blind, parallel-group design. Healthy male and female volunteers (n = 22-23 subjects per dose) received a single oral dose of 2.5, 5, or 30 mg risedronate. Serum and urine samples were collected for 72 and 672 hours, respectively, and risedronate concentrations were determined by ELISA. Safety was evaluated by monitoring adverse events, clinical laboratory measurements, vital signs, and electrocardiograms. Mean Cmax (0.41, 0.94, and 5.1 ng/mL for 2.5, 5, and 30 mg, respectively), AUC (1.8, 3.9, and 21 ng.h/mL for 2.5, 5, and 30 mg, respectively), and urinary excretion (22, 63, and 260 micrograms for 2.5, 5, and 30 mg, respectively) were dose proportional, and there were no significant differences in tmax or CLR among the three doses. All doses were well tolerated; no serious adverse events occurred, and all but one of the adverse events were mild or moderate in severity. There was no evidence of an acute phase reaction occurring after oral administration of risedronate.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J.-Y. Reginster, K. M. Wilson, E. Dumont, B. Bonvoisin, and J. Barrett
Monthly Oral Ibandronate Is Well Tolerated and Efficacious in Postmenopausal Women: Results from the Monthly Oral Pilot Study
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5018 - 5024.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. A Licata
Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Ann. Pharmacother., April 1, 2005; 39(4): 668 - 677.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Barrett, E. Worth, F. Bauss, and S. Epstein
Ibandronate: A Clinical Pharmacological and Pharmacokinetic Update
J. Clin. Pharmacol., September 1, 2004; 44(9): 951 - 965.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. Crandall
Risedronate: A Clinical Review
Arch Intern Med, February 12, 2001; 161(3): 353 - 360.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Clinical Pharmacology